March 1, 2024
Dupixent shows promise in treating severe asthma
New findings from the VESTIGE trial reveal the effectiveness of Dupixent (dupilumab) in managing uncontrolled moderate-to-severe asthma.
Pharmaceuticals, Biotechnology and Life Sciences
Tag: Dupilumab
September 29, 2023
FDA puts Dupixent in priority review for treatment of eosinophilic esophagitis in children younger than 12
Regeneron Pharmaceuticals and Sanofi have received U.S. Food and Drug Administration (FDA) acceptance for Priority Review the supplemental Biologics License Application (sBLA) for Dupixent (dupilumab) to treat children aged 1 to 11 years with eosinophilic esophagitis (EoE).
October 12, 2022
Sanofi, Regeneron: first and only Phase 3 trial in children with EoE shows positive results
Dupixent presented detailed data at this year’s UEG Week conference in Vienna from from an investigational Phase 3 trial showing positive results in children ages 1 to 11 years old who are living with eosinophilic esophagitis (EoE). EoE is a chronic, progressive inflammatory disease that damages the esophagus and prevents it from working properly. Of the approximately 21,000 children under the age of 12 in the U.S. currently being treated for EoE, approximately 9,000 are most in need of new treatment options.
June 1, 2020
Dupixent meets primary and key secondary endpoints in eosinophilic esophagitis trial
Regeneron Pharmaceuticals and Sanofi have shared positive results from Part A of the pivotal Phase 3 trial evaluating Dupixent in patients 12 years and older with eosinophilic esophagitis (EoE), in which the trial met both co-primary endpoints.
May 23, 2020
Sanofi, Regeneron’s Dupixent trial meets both co-primary endpoints
Dupixent in patients 12 years and older with eosinophilic esophagitis (EoE) trial met both of its co-primary endpoints.
May 9, 2019
Dupixent licensed in the EU for severe asthma with type 2 inflammation
The European Commission (EC) has licensed Dupixent (dupilumab), developed by Regeneron and Sanofi, for older than 12 patients as an add-on maintenance treatment for severe asthma with type 2 inflammation.